General Archives - Page 49 of 2367

2 minute read

Spotify Turns Up The Volume On Pricing, Premium Plans See A Hike

June 3, 10:12 AM

Spotify shares surge as the company hiked U.S. premium plan prices. Subscribers will be informed via email about the changes: individual plans rising to $11.99 from $10.99, duo plans to $16.99 from $14.99, and family plans to $19.99 from $16.99. This move aims to boost profit margins amidst competition from Apple and Amazon, focusing on premium services that drive most of Spotify's revenue.

AAPL

2 minute read

Qualcomm Promises New Chips Will Power Unprecedented PC Battery Life

By Shivani Kumaresan

June 3, 9:57 AM

Qualcomm is supplying the semiconductors for Microsoft Corp's latest Copilot+ PCs, which incorporate advanced AI features.

AAPL

2 minute read

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward

By Vandana Singh

June 3, 9:53 AM

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.

GSK

2 minute read

New Boeing CEO Must Learn From Crisis: IATA Head

By Shivani Kumaresan

June 3, 9:50 AM

Boeing Co. continues to grapple with safety issues, worsened by a recent incident involving a midair panel blowout on a 737 MAX plane.

2 minute read

Elon Musk’s Potential Purchase Of House From Tesla Director Raises Governance Concerns: Report

By Benzinga Neuro

June 3, 9:49 AM

The eight-member committee was formed to decide on the company's relocation from Delaware to Texas, a move initially proposed by Musk after a court rejected his $56 billion pay package.

TSLA

2 minute read

What’s Happening With Ford’s Shares Today?

By Shivani Kumaresan

June 3, 9:41 AM

Ford plans to offer driverless technology in the next two years, aiming to attract customers with lucrative subscriptions, amid US safety regulator scrutiny.

1 minute read

Precigen Announces Study Data For PRGN-2012 For Recurrent Respiratory Papillomatosis Patients; Phase 1/2 Pivotal Study Met Primary And Efficacy Endpoints

By Benzinga Newsdesk

June 3, 9:31 AM

– Phase 1/2 pivotal study met the primary safety and efficacy endpoints –– 51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012;

PGEN

1 minute read

Kite, A Gilead Company Presents New Data On Yescarta For Relapsed/Refractory Central Nervous System Lymphoma

By Benzinga Newsdesk

June 3, 9:11 AM

-- At Median Follow-Up of 24.2 Months, No Additional Risks of Adverse Events Related to Yescarta Were Observed ---- Findings Also Suggest Efficacy Trend with Median Progression-Free Survival and Durability of Response of

GILD

2 minute read

Tesla Global Shareholders Risk Exclusion Ahead Of Crucial Vote Amid Cross-Border Voting Woes: Report

By Benzinga Neuro

June 3, 9:00 AM

These votes follow a Delaware judge's ruling that questioned the independence of Tesla's board and voided Musk's share option package.

TSLA

1 minute read

Evaxion Presents Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed EVX-01 Vaccine At The ASCO Annual Meeting 2024

By Benzinga Newsdesk

June 3, 8:47 AM

Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melanoma patients Findings further confirm and validate the precision and predictive power of

EVAX